2022 China 10 times growth potential medical enterprise research ｜ Looking for the next world -class great company

From now until August 10, 2022 China ’s 10 -fold growth potential for medical companies investigates and accepts enterprise registration, looking forward to your participation.

In mid -July, the results of the seventh batch of drugs in the country were released. In the past two years, policies such as two -voting, procurement of drugs, and medical insurance directory negotiations have moved to normalization. The medical and health industry is experiencing huge structural adjustments.

Since 2021, investment and financing in the field of medical and health can be described as ups and downs: Many companies in the secondary market have experienced a market value "roller coaster", and the rhythm of investment and financing in the first -level market has also slowed down. Essence The trillion medical track is returning to clinical value and innovation.

Driven by the aging population and the upgrading of medical needs, many opportunities in the big health industry still surge, so that entrepreneurs and investment institutions are willing to go all out. According to the data of Tianyan, in the first half of 2022, the number of medical and health equity financing events reached 768, ranking the top three in the industry, second only to advanced manufacturing and corporate services.

At the same time, investors can also see that investors prefer early entrepreneurial projects, and it is easier to get blessings from institutions with "high -growth potential". In the first half of 2022, the number of financing events in the A -round A and previous financing in the medical and health field reached 547, accounting for over 70%, of which the number of financing events in Series A reached 244.

PE is close to VC, VC is moving towards early incubation, and investors in the medical industry rush to hard technology innovation, looking for 10 times the potential for growth potential. The medical industry does not lack a story of 10 times and even a hundred times transition. Even if the previous research and development process is long, the high growth after the outbreak is the charm of this industry.

Beidinib, the 10 -year sales of Beida Pharmaceutical, has a cumulative sales of 10 billion yuan in 10 years; Zibutinib in Baiji Shenzhou, with global revenue of 1.406 billion yuan in 2021, is still growing rapidly this year. After the new medicine was launched, Rongchang Bio had a total revenue of 1.424 billion yuan in 2021, a year -on -year increase of nearly 50 times. Under the stimulus of the epidemic, Kangshino's revenue in 2021 was 4.3 billion, a year -on -year increase of more than 170 times; IVD companies and upstream raw material manufacturers were 10 times more increasing.

In the big change, the new generation of enterprises are focusing on clinical pain points, breaking through the technology card neck, crossing market difficulties and danger, step by step, through innovative products and services to change the inherent pattern of medical care. We believe that China will also produce more medical companies that can grow 10 times and 100 times, to achieve social value and business value, and to achieve pride in China.

In the past 10 years, 36 氪 has followed up and reported over 4,000 medical startup companies at home and abroad: from the upsurge of Internet medical treatment to the prosperity of consumer medical care; In the cutting -edge cross -edge -crossing field of synthetic creatures, we and the entire platform tens of millions of users pay attention to the trend of the Chinese medical venture capital market together, and also witnessed the rise of companies with 10 times growth potential.

Based on this background, 36 氪 officially launched 2022 China's 10 -fold growth potential for medical companies for investigations. We will collect extensive solicitation to companies in the medical and health industry. The most increasing potential for medical circuit has an innovative enterprise.

From now on, 2022 China ’s 10 -fold growth potential for medical enterprises has been surveyed and accepted by enterprises. Registration will take off on August 10th; in mid -August, summary and sorting out 36 氪 Expert Group/Industry Investors and other experts and research data. The final investigation results were officially announced in the end.

- END -